tiprankstipranks
Kaken Pharmaceutical Co Ltd (JP:4521)
:4521
Want to see JP:4521 full AI Analyst Report?

Kaken Pharmaceutical Co (4521) Price & Analysis

0 Followers

4521 Stock Chart & Stats

¥3712.00
-¥98.00(-2.16%)
At close: 4:00 PM EST
¥3712.00
-¥98.00(-2.16%)

Bulls Say, Bears Say

Bulls Say
Strong Balance SheetVery low leverage and an ~80% equity ratio give Kaken a stable capital structure and financial flexibility. Low debt reduces refinancing risk and interest burden, enabling sustained funding for R&D, lifecycle management and potential M&A, preserving strategic optionality through policy cycles.
High And Sustainable MarginsRobust gross and operating margins reflect pricing power in specialty dermatology and operational efficiency. Sustained margins support internal funding of clinical programs and commercialization, allowing continued product investment and buffer versus pricing pressure and generic erosion over the medium term.
Strong Cash GenerationHigh cash conversion — OCF >2x net income and a notable rise in free cash flow — provides durable internal financing for R&D, capex and shareholder distributions. Reliable cash generation reduces dependence on external funding and increases resilience to cyclical or regulatory shocks.
Bears Say
Recent Revenue DeclineA material revenue decline (~-19% YoY) weakens top-line momentum and can constrain reinvestment and margin leverage. If stemming from product maturity, NHI price adjustments or volume loss, this decline may represent a multi-quarter structural headwind needing new launches or market expansion to reverse.
Volatile Revenue And Cash FlowDocumented volatility in revenue and cash flow, including a free cash flow dip in 2024, complicates multi-year planning and increases forecasting risk. Variable cash availability can disrupt steady R&D investment, commercial rollouts and dividend predictability, raising execution risk over time.
Concentration In Japan NHI SystemReliance on the Japanese NHI reimbursement framework and domestic branded sales exposes Kaken to periodic drug price revisions and aggressive generic competition. This regulatory concentration limits growth runway and makes revenue and margin sustainability highly sensitive to policy and reimbursement changes.

4521 FAQ

What was Kaken Pharmaceutical Co Ltd’s price range in the past 12 months?
Kaken Pharmaceutical Co Ltd lowest stock price was ¥3540.00 and its highest was ¥4445.00 in the past 12 months.
    What is Kaken Pharmaceutical Co Ltd’s market cap?
    Kaken Pharmaceutical Co Ltd’s market cap is ¥146.06B.
      When is Kaken Pharmaceutical Co Ltd’s upcoming earnings report date?
      Kaken Pharmaceutical Co Ltd’s upcoming earnings report date is Aug 12, 2026 which is in 89 days.
        How were Kaken Pharmaceutical Co Ltd’s earnings last quarter?
        Kaken Pharmaceutical Co Ltd released its earnings results on May 13, 2026. The company reported ¥19.7 earnings per share for the quarter, missing the consensus estimate of ¥19.985 by -¥0.285.
          Is Kaken Pharmaceutical Co Ltd overvalued?
          According to Wall Street analysts Kaken Pharmaceutical Co Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Kaken Pharmaceutical Co Ltd pay dividends?
            Kaken Pharmaceutical Co Ltd pays a Semiannually dividend of ¥95 which represents an annual dividend yield of 4.16%. See more information on Kaken Pharmaceutical Co Ltd dividends here
              What is Kaken Pharmaceutical Co Ltd’s EPS estimate?
              Kaken Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Kaken Pharmaceutical Co Ltd have?
              Kaken Pharmaceutical Co Ltd has 44,139,730 shares outstanding.
                What happened to Kaken Pharmaceutical Co Ltd’s price movement after its last earnings report?
                Kaken Pharmaceutical Co Ltd reported an EPS of ¥19.7 in its last earnings report, missing expectations of ¥19.985. Following the earnings report the stock price went down -1.11%.
                  Which hedge fund is a major shareholder of Kaken Pharmaceutical Co Ltd?
                  Currently, no hedge funds are holding shares in JP:4521
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Kaken Pharmaceutical Co Ltd

                    Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

                    Kaken Pharmaceutical Co (4521) Earnings & Revenues

                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Kissei Pharmaceutical Co
                    Towa Pharmaceutical Co
                    Mochida Pharmaceutical Co., Ltd.
                    KYORIN Pharmaceutical Co.,Ltd.
                    SAWAI GROUP HOLDINGS Co., Ltd.

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks